February 27, 2008
Caliper Settles Litigation With Calif. Firm
By Matthew L. Brown
Hopkinton's Caliper Life Sciences and San Diego-based AntiCancer Inc. have ended patent litigation with an agreement to cross-license some of their products.
Both companies have developed technology that allows researchers to attach proteins to specific cell types within genetically modified mice. The proteins cause the selected cells, cancer cells for example, to glow, allowing researchers to track them.
Under the settlement and licensing agreement, Caliper gets the right to sublicense AntiCancer's fluorescent protein optical imaging patents. AntiCancer gets much the same right with regard to certain Caliper imaging patents.
Caliper and AntiCancer will share any revenue generated by the cross-licensing of their imaging technologies and will make no other settlement payments to each other. The two companies also expect to enter into a distribution agreement by which Caliper will market and sell mouse cell lines developed by AntiCancer.
Both companies have developed technology that allows researchers to attach proteins to specific cell types within genetically modified mice. The proteins cause the selected cells, cancer cells for example, to glow, allowing researchers to track them.
Under the settlement and licensing agreement, Caliper gets the right to sublicense AntiCancer's fluorescent protein optical imaging patents. AntiCancer gets much the same right with regard to certain Caliper imaging patents.
Caliper and AntiCancer will share any revenue generated by the cross-licensing of their imaging technologies and will make no other settlement payments to each other. The two companies also expect to enter into a distribution agreement by which Caliper will market and sell mouse cell lines developed by AntiCancer.
WBJ Web Partners
Most Recent
Most Recent
0 Comments